Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
ILMN
$99.96
Illumina
$.79
.80%
ILMN
Earnings Whisper ®
N/A
3rd Quarter September 2025
Consensus: $1.16
Revenue: $1.06 Bil
Thursday
Oct 30
4:05 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, July 31, 2025
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025
What do you expect when ILMN reports earnings?
Beat
Meet
Miss
Where is ILMN's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$102.15
$101.29
$100.63
$99.77
Support
$99.10
$98.24
$97.58
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.
Peers
Coherent
Agilent Technologies
Bio-Rad Laboratories
Harvard Bioscience
Expectations
›
Illumina